GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+27.67%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$245M
AUM Growth
+$245M
(+68%)
Cap. Flow
+$59.9M
Cap. Flow
% of AUM
24.47%
Top 10 Holdings %
Top 10 Hldgs %
56.8%
Holding
43
New
12
Increased
11
Reduced
10
Closed
6
Top Buys
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$18.2M |
| 2 |
Amylyx Pharmaceuticals
AMLX
|
$15.5M |
| 3 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$10.5M |
| 4 |
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
|
$6.98M |
| 5 |
Relmada Therapeutics
RLMD
|
$6.48M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$6.19M |
| 2 |
Merus
MRUS
|
$5.66M |
| 3 |
Amicus Therapeutics
FOLD
|
$5.22M |
| 4 |
Arvinas
ARVN
|
$4.63M |
| 5 |
Cogent Biosciences
COGT
|
$4.48M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $18.8M | 5.27% | 275,000 +50,000 | +22% | +$3.42M |
|
|
RETA
2
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $18.2M | 5.11% | +725,000 | New | +$18.2M |
|
|
3
Relmada Therapeutics
RLMD
$37.2M
| $15.7M | 4.42% | 425,000 +175,000 | +70% | +$6.48M |
|
|
4
Amylyx Pharmaceuticals
AMLX
$836M
| $15.5M | 4.35% | +550,000 | New | +$15.5M |
|
5
Axsome Therapeutics
AXSM
$6.05B
| $13.4M | 3.76% | 300,000 +75,000 | +33% | +$3.35M |
|
|
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $12.2M | 3.43% | 175,000 +65,000 | +59% | +$4.54M |
|
7
Sarepta Therapeutics
SRPT
$1.78B
| $12.2M | 3.41% | 110,000 -20,000 | -15% | -$2.21M |
|
|
CTIC
8
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $11.6M | 3.27% | 2,000,000 +1,200,000 | +150% | +$6.98M |
|
9
Viridian Therapeutics
VRDN
$1.5B
| $11M | 3.08% | 535,000 -65,000 | -11% | -$1.33M |
|
|
RVNC
10
DELISTED
Revance Therapeutics, Inc.
RVNC
| $10.5M | 2.96% | +390,000 | New | +$10.5M |
|
11
Ascendis Pharma
ASND
$11.8B
| $9.81M | 2.75% | 95,000 +20,000 | +27% | +$2.07M |
|
|
12
Cogent Biosciences
COGT
$1.69B
| $8.95M | 2.51% | 600,000 -300,000 | -33% | -$4.48M |
|
13
Vaxcyte
PCVX
$4B
| $8.64M | 2.43% | 360,000 +35,000 | +11% | +$840K |
|
|
ISEE
14
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $8.32M | 2.34% | 463,700 -36,300 | -7% | -$651K |
|
|
KRTX
15
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $6.75M | 1.89% | 30,000 -15,000 | -33% | -$3.37M |
|
16
BioCryst Pharmaceuticals
BCRX
$1.74B
| $6.62M | 1.86% | 525,000 +200,000 | +62% | +$2.52M |
|
17
Altimmune
ALT
$338M
| $5.56M | 1.56% | +435,000 | New | +$5.56M |
|
|
18
Amicus Therapeutics
FOLD
$2.34B
| $5.22M | 1.47% | 500,000 -500,000 | -50% | -$5.22M |
|
19
Syndax Pharmaceuticals
SNDX
$1.41B
| $4.81M | 1.35% | 200,000 -25,000 | -11% | -$601K |
|
|
HZNP
20
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $4.64M | 1.3% | 75,000 -25,000 | -25% | -$1.55M |
|
21
Astria Therapeutics
ATXS
$349M
| $4.52M | 1.27% | +500,000 | New | +$4.52M |
|
22
Kezar Life Sciences
KZR
$28.9M
| $4.52M | 1.27% | 525,000 +75,000 | +17% | +$646K |
|
|
BPMC
23
DELISTED
Blueprint Medicines
BPMC
| $4.28M | 1.2% | +65,000 | New | +$4.28M |
|
|
WHWK
24
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $2.83M | 0.79% | 200,000 +50,000 | +33% | +$707K |
|
|
ITCI
25
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $2.79M | 0.78% | +60,000 | New | +$2.79M |
|